stockrow
Friday 6 November 2026
Export BLRX’s income statement to Excel — free account
BioLineRx Ltd.
BLRX Healthcare Biotechnology
BioLineRx Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 95.9% from fiscal 2024.
- Revenue
- −3.29%
- EPS
- +31.9%
- Free cash flow
- −1,827.7%
- Total debt
- −40.2%
Quarter to June 2026, against a year earlier
1.77
0.09
−4.84%
Follow BLRX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (38.10%) | (37.91%) | (6.38%) | (21.24%) |
+8 more TTM periods Free account |
|
| (18.21%) | (19.20%) | (2.94%) | (6.43%) | ||
ROIC |
(74.28%) | (60.18%) | (56.36%) | (160.93%) | |
Return on Tangible Assets |
(249.61%) | (97.52%) | (10.03%) | (19.82%) | |
Average Days of Receivables |
190.89 | 492.31 | 141.05 | 20.03 | |
Free Cash Flow per Share |
(2.43) | (1.75) | (1.97) | (3.10) | |
Free Cash Flow |
(10.81) | (7.78) | (8.11) | (13.48) | |
Capital Expenditures |
0.00 | (0.01) | (0.04) | — | |
| Other line items | |||||
Cash ROIC |
(29.69%) | (16.90%) | (15.26%) | (24.60%) | |
Accounts Receivable Turnover |
2.76 | 0.74 | 0.54 | 5.47 | |
Accounts Payable Turnover |
0.04 | 0.04 | 0.03 | 0.92 | |
Inventory Turnover |
0.11 | 0.11 | 0.09 | 2.19 | |
Average Days of Payables |
8,534.17 | 8,973.23 | 8,309.30 | 329.25 | |
Days of Inventory on Hand |
2,845.16 | 2,705.52 | 3,408.78 | 126.78 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
690.73% | 641.80% | 685.85% | 59.15% | |
Selling, General and Administrative Expense of Revenue |
263.58% | 214.91% | 266.44% | 72.56% | |
Share Based Compensation of Revenue |
21.98% | 19.97% | 33.56% | 1.52% | |
Interest Coverage |
(11.68) | (9.82) | (8.04) | (2.07) | |
Operating CF/Net income |
1.55 | 0.98 | 6.87 | 4.53 | |
Depreciation/Fixed assets |
2.68 | 3.05 | 3.27 | 13.76 | |
Capex/Depreciation |
(0.01) | (0.03) | (0.07) | 0.00 | |
Revenue per Share |
0.31 | 0.32 | 0.29 | 2.93 | |
Operating CF per Share |
(2.43) | (1.75) | (1.96) | (3.10) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.03 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026